Cellectar Biosciences (CLRB) versus Sagent Pharmaceuticals (SGNT) Head-To-Head Contrast

Cellectar Biosciences (NASDAQ: CLRB) and Sagent Pharmaceuticals (NASDAQ:SGNT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Valuation & Earnings

This table compares Cellectar Biosciences and Sagent Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cellectar Biosciences N/A N/A -$10.78 million ($1.24) -1.29
Sagent Pharmaceuticals N/A N/A N/A ($0.76) -28.59

Sagent Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cellectar Biosciences and Sagent Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectar Biosciences N/A -97.36% -83.40%
Sagent Pharmaceuticals -0.72% -0.81% -0.59%

Risk and Volatility

Cellectar Biosciences has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Sagent Pharmaceuticals has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Institutional & Insider Ownership

2.4% of Cellectar Biosciences shares are owned by institutional investors. 10.2% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Cellectar Biosciences and Sagent Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences 0 0 2 0 3.00
Sagent Pharmaceuticals 0 0 0 0 N/A

Cellectar Biosciences currently has a consensus price target of $2.70, indicating a potential upside of 68.75%. Given Cellectar Biosciences’ higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than Sagent Pharmaceuticals.

Summary

Cellectar Biosciences beats Sagent Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Sagent Pharmaceuticals Company Profile

Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company’s operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply